Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab with or without lenalidomide versus R-GemOx in relapsed or refractory diffuse large B-cell lymphoma
jRCT2031240247Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) comparing Epcoritamab Plus Lenalidomide, Rituximab Plus Gemcitabine and Oxaliplatin and Epcoritamab (3 arms). Primary endpoint: Progression-Free Survival. Started Aug 2024; status: active, not recruiting.
02
Drugs
epcoritamablenalidomiderituximabgemcitabineoxaliplatin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2031240247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240247.